HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis

Inclusion Criteria: * Diagnosis of seborrheic dermatitis of the scalp * PGA of 2 (mild) or greater at baseline * TDSS score at baseline of 2 or greater, for both scaling and inflammation * Must agree to use of non-medicated shampoos during study period; must refrain from use of other medicated scalp products during the trial Exclusion Criteria: * Use of any topical or oral products that would affect assessment of the scalp SD condition, in the opinion of the primary investigator, within the following periods prior to baseline: * Medicated shampoos within 2 weeks of baseline * Topical scalp medications within 2 weeks of baseline * Oral medications affecting the scalp within 4 weeks of baseline * Other medications determined by the investigator to potentially affect the assessment of SD = washout to be determined by the investigator, as appropriate to the known medication properties * Any current or past medical condition, including active dermatitis or any other dermatological condition, which might interfere with assessment of dandruff * Patients using any medications that may increase photosensitivity, and thus pose a risk when undergoing LaserComb therapy * Patients with known adverse reactions, allergy or hypersensitivity to laser light components/light sensitivity conditions * Patients who have received any investigational drug within 30 days prior to study entry.